Oramed Advances Oral Insulin Program, Reports Strong Portfolio Returns, Plans Dividend

Oramed Pharmaceuticals is advancing its oral insulin program independently and has launched a new US trial. The company is experiencing strong returns from its diversified investment portfolio and is accelerating growth through strategic partnerships, innovation, and value-driven expansion. Oramed reaffirms its commitment to rewarding shareholders, including plans for a one-time dividend.